THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES

Header Logo

Connection

Joan Walker to Ovarian Neoplasms

Back to Details
This is a "connection" page, showing publications Joan Walker has written about Ovarian Neoplasms.
Joan Walker
Connection Strength
8.006
Ovarian Neoplasms
  1. Reply to F. Tomao et al and E.A. De Jaeghere et al. J Clin Oncol. 2019 11 20; 37(33):3170.
    View in: PubMed
    Score: 0.434
  2. Role of Intraperitoneal Therapy in the Initial Management of Ovarian Cancer. J Clin Oncol. 2019 09 20; 37(27):2416-2419.
    View in: PubMed
    Score: 0.430
  3. Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. J Clin Oncol. 2019 06 01; 37(16):1380-1390.
    View in: PubMed
    Score: 0.421
  4. Intraperitoneal chemotherapy for ovarian cancer. Gynecol Oncol. 2016 07; 142(1):1-2.
    View in: PubMed
    Score: 0.346
  5. Society of Gynecologic Oncology recommendations for the prevention of ovarian cancer. Cancer. 2015 Jul 01; 121(13):2108-20.
    View in: PubMed
    Score: 0.317
  6. Intraperitoneal chemotherapy requires expertise and should be the standard of care for optimally surgically resected epithelial ovarian cancer patients. Ann Oncol. 2013 Dec; 24 Suppl 10:x41-45.
    View in: PubMed
    Score: 0.290
  7. Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study. Gynecol Oncol. 2013 Jul; 130(1):12-8.
    View in: PubMed
    Score: 0.277
  8. A phase I study with an expanded cohort to assess feasibility of intravenous docetaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with previously untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 Dec; 127(3):506-10.
    View in: PubMed
    Score: 0.266
  9. A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 Apr; 125(1):54-8.
    View in: PubMed
    Score: 0.253
  10. Phase II trial of intraperitoneal cisplatin combined with intravenous paclitaxel in patients with ovarian, primary peritoneal and fallopian tube cancer. Gynecol Oncol. 2011 Sep; 122(3):527-31.
    View in: PubMed
    Score: 0.244
  11. Docetaxel plus trabectedin appears active in recurrent or persistent ovarian and primary peritoneal cancer after up to three prior regimens: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 2011 Mar; 120(3):459-63.
    View in: PubMed
    Score: 0.236
  12. Intraperitoneal chemotherapy for ovarian cancer: 2009 goals. Gynecol Oncol. 2009 Mar; 112(3):439-40.
    View in: PubMed
    Score: 0.208
  13. Intraperitoneal chemotherapy for patients with advanced epithelial ovarian cancer: a review of complications and completion rates. Gynecol Oncol. 2008 Feb; 108(2):342-7.
    View in: PubMed
    Score: 0.190
  14. Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment. J Clin Oncol. 2006 Feb 20; 24(6):988-94.
    View in: PubMed
    Score: 0.169
  15. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecol Oncol. 2006 Jan; 100(1):27-32.
    View in: PubMed
    Score: 0.167
  16. Can frequency and severity of symptoms predict the presence of ovarian cancer? Nat Clin Pract Oncol. 2004 Dec; 1(2):72-3.
    View in: PubMed
    Score: 0.155
  17. Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study. J Clin Oncol. 2024 Jul 20; 42(21):2537-2545.
    View in: PubMed
    Score: 0.150
  18. Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study. J Clin Oncol. 2022 Dec 01; 40(34):3965-3974.
    View in: PubMed
    Score: 0.134
  19. Symptoms of Women With High-Risk Early-Stage Ovarian Cancer. Obstet Gynecol. 2022 02 01; 139(2):157-162.
    View in: PubMed
    Score: 0.128
  20. Prognostic significance of ethnicity and age in advanced stage epithelial ovarian cancer: An NRG oncology/gynecologic oncology group study. Gynecol Oncol. 2022 02; 164(2):398-405.
    View in: PubMed
    Score: 0.126
  21. Patient-reported outcome changes at the end of life in recurrent platinum-resistant ovarian cancer: An NRG oncology/GOG study. Gynecol Oncol. 2021 11; 163(2):392-397.
    View in: PubMed
    Score: 0.124
  22. Post hoc analyses of GOG 9923: Does BRCA status affect toxicities?: An NRG oncology study. Gynecol Oncol. 2021 05; 161(2):512-515.
    View in: PubMed
    Score: 0.119
  23. Prospective follow-up of quality of life for participants undergoing risk-reducing salpingo-oophorectomy or ovarian cancer screening in GOG-0199: An NRG Oncology/GOG study. Gynecol Oncol. 2020 01; 156(1):131-139.
    View in: PubMed
    Score: 0.110
  24. Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer. N Engl J Med. 2019 11 14; 381(20):1929-1939.
    View in: PubMed
    Score: 0.109
  25. A phase I study of intravenous or intraperitoneal platinum based chemotherapy in combination with veliparib and bevacizumab in newly diagnosed ovarian, primary peritoneal and fallopian tube cancer. Gynecol Oncol. 2020 01; 156(1):13-22.
    View in: PubMed
    Score: 0.109
  26. Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study. Gynecol Oncol. 2018 11; 151(2):257-263.
    View in: PubMed
    Score: 0.101
  27. A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254). Gynecol Oncol. 2018 08; 150(2):247-252.
    View in: PubMed
    Score: 0.099
  28. Quality of life, symptoms and care needs in patients with persistent or recurrent platinum-resistant ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2018 07; 150(1):119-126.
    View in: PubMed
    Score: 0.099
  29. Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin®) in recurrent ovarian, tubal, or peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 09; 146(3):477-483.
    View in: PubMed
    Score: 0.093
  30. Multiplex profiling identifies distinct local and systemic alterations during intraperitoneal chemotherapy for ovarian cancer: An NRG Oncology/Gynecologic Oncology Group Study. Gynecol Oncol. 2017 07; 146(1):137-145.
    View in: PubMed
    Score: 0.092
  31. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017 06; 18(6):779-791.
    View in: PubMed
    Score: 0.092
  32. A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 05; 145(2):236-242.
    View in: PubMed
    Score: 0.091
  33. Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 04; 145(1):122-129.
    View in: PubMed
    Score: 0.090
  34. CT Perfusion as an Early Biomarker of Treatment Efficacy in Advanced Ovarian Cancer: An ACRIN and GOG Study. Clin Cancer Res. 2017 Jul 15; 23(14):3684-3691.
    View in: PubMed
    Score: 0.090
  35. Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic Oncology Group study ancillary study. Gynecol Oncol. 2016 Dec; 143(3):484-489.
    View in: PubMed
    Score: 0.088
  36. Integrative Development of a TLR8 Agonist for Ovarian Cancer Chemoimmunotherapy. Clin Cancer Res. 2017 04 15; 23(8):1955-1966.
    View in: PubMed
    Score: 0.088
  37. Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. J Clin Oncol. 2016 07 01; 34(19):2279-86.
    View in: PubMed
    Score: 0.086
  38. Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer. N Engl J Med. 2016 Feb 25; 374(8):738-48.
    View in: PubMed
    Score: 0.085
  39. Update on Intraperitoneal Chemotherapy for the Treatment of Epithelial Ovarian Cancer. Am Soc Clin Oncol Educ Book. 2016; 35:143-51.
    View in: PubMed
    Score: 0.084
  40. Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: an NRG Oncology/GOG study. Gynecol Oncol. 2015 Oct; 139(1):17-22.
    View in: PubMed
    Score: 0.081
  41. Consensus in controversy: The modified Delphi method applied to Gynecologic Oncology practice. Gynecol Oncol. 2015 Sep; 138(3):712-6.
    View in: PubMed
    Score: 0.081
  42. Catumaxomab for the treatment of malignant ascites in patients with chemotherapy-refractory ovarian cancer: a phase II study. Int J Gynecol Cancer. 2014 Nov; 24(9):1583-9.
    View in: PubMed
    Score: 0.077
  43. Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199. J Clin Oncol. 2014 Oct 10; 32(29):3275-83.
    View in: PubMed
    Score: 0.076
  44. Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study. J Clin Oncol. 2014 Apr 20; 32(12):1210-7.
    View in: PubMed
    Score: 0.074
  45. Hypogastric artery aneurysm masquerading as an ovarian neoplasm. Gynecol Oncol. 1992 Dec; 47(3):382-4.
    View in: PubMed
    Score: 0.068
  46. A phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 May; 125(2):367-71.
    View in: PubMed
    Score: 0.064
  47. Serum profiling to distinguish early- and late-stage ovarian cancer patients from disease-free individuals. Cancer Invest. 2012 Feb; 30(2):189-97.
    View in: PubMed
    Score: 0.063
  48. A phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol. 2011 May 01; 121(2):264-8.
    View in: PubMed
    Score: 0.060
  49. Adjuvant chemotherapy for the "oldest old" ovarian cancer patients: can we anticipate toxicity-related treatment failure in a vulnerable population? Cancer. 2009 Apr 01; 115(7):1472-80.
    View in: PubMed
    Score: 0.052
  50. Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis. Gynecol Oncol. 2009 Feb; 112(2):337-41.
    View in: PubMed
    Score: 0.051
  51. Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer. J Clin Oncol. 2008 Jun 01; 26(16):2674-82.
    View in: PubMed
    Score: 0.049
  52. Ovarian cancer in the octogenarian: does the paradigm of aggressive cytoreductive surgery and chemotherapy still apply? Gynecol Oncol. 2008 Aug; 110(2):133-9.
    View in: PubMed
    Score: 0.049
  53. Validation of FACT/GOG-AD subscale for ovarian cancer-related abdominal discomfort: a Gynecologic Oncology Group study. Gynecol Oncol. 2008 Jul; 110(1):60-4.
    View in: PubMed
    Score: 0.049
  54. Results of the 2006 Innsbruck International Consensus Conference on intraperitoneal chemotherapy in patients with ovarian cancer. Cancer. 2007 Feb 15; 109(4):645-9.
    View in: PubMed
    Score: 0.045
  55. Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007 Feb 01; 25(4):437-43.
    View in: PubMed
    Score: 0.045
  56. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2006 Sep; 102(3):432-9.
    View in: PubMed
    Score: 0.043
  57. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006 Jan 05; 354(1):34-43.
    View in: PubMed
    Score: 0.042
  58. Carcinosarcoma of the ovary-a case series. Gynecol Oncol. 2006 Jan; 100(1):128-32.
    View in: PubMed
    Score: 0.041
  59. Optimization of Timing for Risk-Reducing Salpingectomy and Oophorectomy. Obstet Gynecol. 2025 Jan 01; 145(1):21-30.
    View in: PubMed
    Score: 0.039
  60. Laparoscopic pelvic and paraaortic lymph node dissection: analysis of the first 100 cases. Gynecol Oncol. 2001 Sep; 82(3):498-503.
    View in: PubMed
    Score: 0.031
  61. Low-dose abdominal radiation as a docetaxel chemosensitizer for recurrent epithelial ovarian cancer: a phase I study of the Gynecologic Oncology Group. Gynecol Oncol. 2011 Feb; 120(2):224-8.
    View in: PubMed
    Score: 0.015
  62. A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: a Gynecologic Oncology Group Study (GOG 146Q). Gynecol Oncol. 2011 Mar; 120(3):454-8.
    View in: PubMed
    Score: 0.015
  63. Incidence and location of para-aortic lymph node metastases in gynecologic malignancies. J Am Coll Surg. 1995 Jul; 181(1):72-4.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES